Candriam S.C.A. Coherus Bio Sciences, Inc. Transaction History

Candriam S.C.A.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 20, 2021	SELL	$12.95 - $15.41 $8.82 Million - $10.5 Million	-680,812 Closed	0 $0
Q1 2021 Apr 29, 2021	SELL	$14.42 - $21.39 $648 - $962	-45 Reduced 0.01%	680,812 $11.4 Million
Q4 2020 Jan 22, 2021	SELL	$16.56 - $18.94 $450,316 - $515,035	-27,193 Reduced 3.84%	680,857 $11.8 Million
Q3 2020 Oct 19, 2020	BUY	$17.41 - $19.89 $725,613 - $828,975	41,678 Added 6.25%	708,050 $13 Million
Q2 2020 Jul 23, 2020	BUY	$14.43 - $19.16 $4.74 Million - $6.3 Million	328,577 Added 97.27%	666,372 $11.9 Million
Q1 2020 May 26, 2020	BUY	$11.67 - $22.53 $863 - $1,667	74 Added 0.02%	337,795 $5.95 Million
Q4 2019 Jan 21, 2020	BUY	$16.33 - $21.37 $2.71 Million - $3.54 Million	165,802 Added 96.44%	337,721 $6,000
Q3 2019 Oct 21, 2019	BUY	$16.3 - $23.37 $1.74 Million - $2.5 Million	106,919 Added 164.49%	171,919 $3,000
Q2 2019 Aug 01, 2019	BUY	$13.1 - $22.1 $851,500 - $1.44 Million	65,000 New	65,000 $1.43 Million
Q2 2018 Aug 14, 2018	SELL	$10.25 - $17.45 $871,250 - $1.48 Million	-85,000 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$9.1 - $13.7 $509,600 - $767,200	-56,000 Reduced 39.72%	85,000 $939,000
Q4 2017 Feb 07, 2018	SELL	$8.35 - $14.4 $434,200 - $748,800	-52,000 Reduced 26.94%	141,000 $1.24 Million
Q3 2017 Nov 03, 2017	BUY	$11.1 - $14.5 $2.14 Million - $2.8 Million	193,000	193,000 $2.58 Million

135

78.3M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $59.8M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.